Amitriptyline (amityptilline) coated tablets 0.025 №50

Amitriptyline (amityptilline) coated tablets 0.025 №50

$12.80

Manufacturer: Ukraine

Amitriptyline is a tricyclic antidepressant. It is indicated for:

  • Severe depression, especially with characteristic signs of anxiety, agitation and sleep disturbance.
  • Depressive states in patients with schizophrenia – in combination with an antipsychotic to prevent exacerbations of hallucinations and paranoid mania.
  • Chronic pain syndrome.
  • Nocturnal enuresis in the absence of organic pathology.
Category:

Description

Ingredients

active ingredient: amitriptyline;

1 tablet contains amitriptyline hydrochloride in terms of amitriptyline 25 mg;

excipients: lactose monohydrate; microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, anhydrous colloidal silicon dioxide, polyethylene glycol 6000, titanium dioxide (E 171), talc, polysorbate 80, carmoisine (E 122).

Dosage form

Coated tablets.

Basic physical and chemical properties: round-shaped, film-coated tablets, from light pink to pink in color, with top and bottom convex surfaces. On the fault, under a magnifying glass, you can see the core, surrounded by one continuous layer.

Pharmacotherapeutic group

Antidepressants. Non-selective monoamine reuptake inhibitors. ATX code N06A A09.

Pharmacodynamics

Amitriptyline is a tricyclic antidepressant. Amitriptyline is a tertiary amine that occupies a central place among tricyclic antidepressants, since it is approximately equally active in vivo as an inhibitor of the uptake of serotonin and norepinephrine by presynaptic nerve endings. The main metabolite of the compound, nortriptyline, is a relatively stronger inhibitor of norepinephrine reuptake, but also blocks serotonin reuptake. Amitriptyline has fairly strong anticholinergic, antihistaminergic and sedative properties and also potentiates the effects of catecholamines.

Inhibition of rapid eye movement (REM) sleep is considered a sign of antidepressant activity. Tricyclic antidepressants, like selective serotonin reuptake inhibitors and monoamine oxidase inhibitors (MAOIs), inhibit the REM phase and increase deep slow-wave sleep.

Amitriptyline increases pathologically reduced mood levels.

Due to its sedative effect, amitriptyline is of particular importance in the treatment of depression, which is accompanied by anxiety, agitation, restlessness and sleep disturbances. The antidepressant effect usually develops after 2-4 weeks of therapy, while the sedative effect does not decrease.

The analgesic effect of the drug is not related to the antidepressant, since analgesia occurs much earlier than any mood changes, and often as a result of taking a much lower dose than is necessary to provide mood changes.

Indications

Severe depression, especially with characteristic signs of anxiety, agitation and sleep disturbance.

Depressive states in patients with schizophrenia – in combination with an antipsychotic to prevent exacerbations of hallucinations and paranoid mania.

Chronic pain syndrome.

Nocturnal enuresis in the absence of organic pathology.

Contraindications

Hypersensitivity to amitriptyline or any of the components of the drug.

Recent myocardial infarction. Any kind of blockade or disturbance of the rhythm of the heart, as well as insufficiency of the coronary arteries.

Simultaneous treatment with the use of MAOIs (monoamine oxidase inhibitors) is contraindicated (see the section “Interaction with other medicinal products and other types of interactions”).

Simultaneous administration of amitriptyline and MAOIs can cause the development of serotonin syndrome (a combination of symptoms that include agitation, confusion, tremor, myoclonus and hyperthermia).

Treatment with amitriptyline can be initiated 14 days after discontinuation of irreversible non-selective MAOIs and at least 1 day after discontinuation of the reversible drugs moclobemide and selegiline.

Treatment with MAOIs can begin 14 days after stopping amitriptyline.

Directions

Depression. 

Treatment should be initiated at low doses and gradually increased while closely monitoring clinical response and signs of drug sensitivity. Doses of more than 150 mg per day (up to 225 mg per day, and sometimes up to 300 mg per day) should be used in a hospital setting.

Adults: Initially 25 mg 3 times a day, gradually increasing if necessary by 25 mg every second day to 150 mg per day (occasionally up to 225–300 mg per day in a hospital setting).

The maintenance dose corresponds to the optimal therapeutic dose.

Patients over 65 years of age: Treatment should be initiated at approximately half the recommended dose, using an appropriate dosage form of Amitriptyline tablets, gradually increasing every other day, if necessary, to 100–150 mg per day. An additional dose should usually be taken in the evening. The maintenance dose corresponds to the optimal therapeutic dose.

duration of therapy. The antidepressant effect usually develops within 2-4 weeks. Treatment with antidepressants is symptomatic and should therefore be continued for an appropriate period of time, usually up to 6 months after recovery, to prevent relapse. Patients with recurrent (unipolar) depression may need maintenance therapy for several years to prevent new episodes.

Chronic pain syndrome.

Adults. Initially, 25 mg should be taken in the evening. The dose can be gradually increased according to the effect of therapy up to a maximum dose of 100 mg in the evening.

For elderly patients, treatment should begin at about half the recommended dose.

Nocturnal enuresis.

Children 7-12 years old – 25 mg, over 12 years old – 50 mg in 30 minutes – 1 hour before bedtime.

Duration of therapy – no more than 3 months.

Decreased renal function: Patients with reduced renal function can be given amitriptyline at normal doses.

Decreased liver function: careful dose selection and, if possible, determination of the drug content in serum is recommended.

Method of application: increasing the dose is usually carried out by taking Amitriptyline tablets in the evening or at bedtime. With maintenance therapy, the total daily dose can be taken as a single dose, mainly at bedtime. Amitriptyline tablets should be swallowed whole, without chewing and with water.

Discontinuation of treatment: in case of discontinuation of treatment, the dose of Amitriptyline tablets should be gradually reduced over several weeks.

Related products